Janux Therapeutics JANX Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Janux Therapeutics's net unrealized gains (losses) on securities still held?
- Janux Therapeutics (JANX) reported net unrealized gains (losses) on securities still held of -$3.74M in Q1 2026.
- How has Janux Therapeutics's net unrealized gains (losses) on securities still held changed year-over-year?
- Janux Therapeutics's net unrealized gains (losses) on securities still held decreased by 334.8% year-over-year, from $1.59M to -$3.74M.
- What does net unrealized gains (losses) on securities still held mean?
- This metric captures the change in the fair value of investment securities held by the company that has not yet been realized through a sale. It reflects market-driven fluctuations in the value of the company's investment portfolio, net of tax effects. While not part of net income, it provides insight into the volatility and performance of the company's treasury or investment strategy.